Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis Underscores unmet need for a ...
Monthly Prescribing Reference3d
Encapsulated Rapamycin Fast Tracked for Familial Adenomatous Polyposis
The Fast Track designation is supported by data from a phase 2 trial that evaluated eRapa in 30 adult patients with FAP.
Nasdaq4d
FDA Grants Fast Track Designation To Biodexa's ERapa For Familial Adenomatous Polyposis
has been granted Fast Track Designation by the U.S. Food and Drug Administration or FDA for the treatment of Familial Adenomatous Polyposis or FAP. eRapa is a proprietary encapsulated form of ...
Biodexa Pharmaceuticals receives Fast Track designation for eRapa
Biodexa Pharmaceuticals (BDRX) received Fast Track status from the U.S. Food and Drug Administration for eRapa, a proprietary encapsulated form ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Biodexa Pharmaceuticals PLC: Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status
CARDIFF, UK / ACCESS Newswire / February 12, 2025 / Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatmen ...
Biodexa Pharmaceuticals ADRs Rise After Cancer Drug Gets FDA Fast-Track Designation
The U.K. biopharmaceutical company said data from a Phase 2 study of eRapa, a treatment for familial adenomatous polyposis, showed the drug to be safe and well-tolerated among users. The treatment ...
Targeted Oncology1d
Balancing Symptoms and Current Therapies in Desmoid Tumor Management
What does the Desmoid Tumor Working Group recommend for patients with potential desmoid tumors? 1. Nam Quoc Bui, MD: The ...